BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Instructions to Improve Your Mental Exploration with Cutting edge Measurements - 2Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
- 3Guinea-Bissau's coup called a 'sham' by West African political figures
- 4The 10 Most Persuasive Forerunners in Innovation
- 5Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Vote In favor of Your Favored Kind Of Vegetable
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- Top Frozen yogurt Flavor: Cast Your Vote!
- 7 Heavenly Espressos, One Do You Like?
- Immortal Style: Closet Staples for Each Age
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
